nach oben

Acta Diabetologica

Erschienen in:

11.11.2017 | Original Article

Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis

verfasst von: Vivian Yawei Guo, Bing Cao, Chunyan Cai, Kenneth King-yip Cheng, Bernard Man Yung Cheung

Erschienen in: Acta Diabetologica | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims

Fetuin-A has been linked to insulin resistance and obesity. Its role in the pathogenesis of type 2 diabetes (T2DM) has also been discussed. We aimed to investigate the prospective association of fetuin-A and the risk of T2DM in a systematic review and meta-analysis.

Methods

A systematic search of studies from the MEDLINE, EMBASE, Pubmed and Web of Science using fetuin-A, diabetes and various synonyms was conducted up to June 5, 2017. Relevant studies were extracted by two reviewers independently. The quality of studies was assessed using Newcastle–Ottawa scales. Overall estimates were pooled using fixed effect with inverse variance meta-analysis. Subgroup analyses by gender, study population, techniques of assessing fetuin-A, diabetes ascertainment methods, follow-up duration and measures of association were conducted.

Results

Seven studies comprising a total of 11,497 individuals and 2176 cases of T2DM were included in the systematic review and meta-analysis. Overall, one SD increment of fetuin-A level was associated with a 23% greater risk of incident T2DM (RR: 1.23, 95% CI 1.16–1.31). No significant heterogeneity or publication bias was found. The association was relatively stable across different subgroups. However, the association seemed only evident in women, but not in men.

Conclusions

Higher circulating fetuin-A levels were associated with increased risk of T2DM. However, the causality deserved further analysis.

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149CrossRefPubMed

Guo VY, Cao B, Wong CKH, Yu EYT (2017) The association between daytime napping and risk of diabetes: a systematic review and meta-analysis of observational studies. Sleep Med 37:105–112

Guo VY, Yu EY, Wong C et al (2016) Validation of a nomogram for predicting regression from impaired fasting glucose to normoglycaemia to facilitate clinical decision making. Fam Pract 33:401–407CrossRefPubMedPubMedCentral

Vazquez G, Duval S, Jacobs DR Jr, Silventoinen K (2007) Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev 29:115–128CrossRefPubMed

Lawlor DA, Ebrahim S, Davey Smith G (2002) The association between components of adult height and Type II diabetes and insulin resistance: British Women’s Heart and Health Study. Diabetologia 45:1097–1106CrossRefPubMed

Stefan N, Haring HU, Hu FB, Schulze MB (2016) Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications. Lancet Diabetes Endocrinol 4:457–467CrossRefPubMed

Scott LJ, Mohlke KL, Bonnycastle LL et al (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341–1345CrossRefPubMedPubMedCentral

Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885CrossRefPubMed

Stefan N, Fritsche A, Schick F, Haring HU (2016) Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 4:789–798CrossRefPubMed

10.

Noble D, Mathur R, Dent T, Meads C, Greenhalgh T (2011) Risk models and scores for type 2 diabetes: systematic review. BMJ 343:d7163CrossRefPubMedPubMedCentral

11.

Srinivas PR, Wagner AS, Reddy LV et al (1993) Serum alpha(2)-Hs-glycoprotein is an inhibitor of the human insulin-receptor at the tyrosine kinase level. Mol Endocrinol 7:1445–1455PubMed

12.

Auberger P, Falquerho L, Contreres JO et al (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58:631–640CrossRefPubMed

13.

Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G (2006) Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 350:437–443CrossRefPubMed

14.

Mathews ST, Singh GP, Ranalletta M et al (2002) Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51:2450–2458CrossRefPubMed

15.

Hennige AM, Staiger H, Wicke C et al (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 3:e1765CrossRefPubMedPubMedCentral

16.

Stefan N, Hennige AM, Staiger H et al (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853–857CrossRefPubMed

17.

Mori K, Emoto M, Yokoyama H et al (2006) Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29:468CrossRefPubMed

18.

Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3–19CrossRefPubMed

19.

Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195–1200CrossRefPubMed

20.

Lorant DP, Grujicic M, Hoebaus C et al (2011) Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care 34:156–161CrossRefPubMed

21.

Reinehr T, Karges B, Meissner T et al (2015) Fibroblast growth factor 21 and fetuin-A in obese adolescents with and without type 2 diabetes. J Clin Endocrinol Metab 100:3004–3010CrossRefPubMed

22.

Song A, Xu M, Bi Y et al (2011) Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS ONE 6:e19228CrossRefPubMedPubMedCentral

23.

Ou HY, Yang C, Wu HT, Wu JS, Lu FH, Chang CJ (2011) Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol 75:450–455CrossRef

24.

Aroner SA, Mukamal KJ, St-Jules DE et al (2017) Fetuin-A and risk of diabetes independent of liver fat content the multi-ethnic study of atherosclerosis. Am J Epidemiol 185:54–64CrossRefPubMed

25.

Dutta D, Mondal SA, Kumar M et al (2014) Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India. Diabet Med 31:1594–1599CrossRefPubMed

26.

Ix JH, Biggs ML, Mukamal KJ et al (2012) Association of fetuin-A with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation 125:2316–2322CrossRefPubMedPubMedCentral

27.

Ix JH, Wassel CL, Kanaya AM et al (2008) Fetuin-A and incident diabetes mellitus in older persons. JAMA 300:182–188CrossRefPubMedPubMedCentral

28.

Laughlin GA, Barrett-Connor E, Cummins KM, Daniels LB, Wassel CL, Ix JH (2013) Sex-specific association of fetuin-A with type 2 diabetes in older community-dwelling adults The Rancho Bernardo Study. Diabetes Care 36:1994–2000CrossRefPubMedPubMedCentral

29.

Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57:2762–2767CrossRefPubMedPubMedCentral

30.

Sun Q, Cornelis MC, Manson JE, Hu FB (2013) Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 62:49–55CrossRefPubMed

31.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al (2017) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed June, 2017

32.

Chene G, Thompson SG (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144:610–621CrossRefPubMed

33.

Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482CrossRefPubMed

34.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed

35.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentral

36.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed

37.

Stefan N, Sun Q, Fritsche A et al (2014) Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS ONE 9:e92238CrossRefPubMedPubMedCentral

38.

Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM (2017) The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest. https://doi.org/10.1007/s40618-017-0697-8

39.

Lin X, Braymer HD, Bray GA, York DA (1998) Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. Life Sci 63:145–153CrossRefPubMed

40.

Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA (2006) Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113:1760–1767CrossRefPubMedPubMedCentral

41.

Xu Y, Xu M, Bi YF et al (2011) Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 216:180–186CrossRefPubMed

42.

Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G (2010) Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab 95:4877–4881CrossRefPubMed

43.

Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4–7CrossRefPubMed

44.

Dasgupta S, Bhattacharya S, Biswas A et al (2010) NF-kappa B mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem J 429:451–462CrossRefPubMed

45.

Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285CrossRefPubMed

46.

Stefan N, Haring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19:394–395CrossRefPubMed

47.

Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546CrossRefPubMed

48.

Daniele G, Guardado Mendoza R, Winnier D et al (2014) The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131CrossRefPubMed

49.

Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91CrossRefPubMed

50.

Federici M, Hribal ML, Menghini R et al (2005) Timp3 deficiency in insulin receptor–haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494–3505CrossRefPubMedPubMedCentral

51.

Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56:2153–2163CrossRefPubMed

52.

Vionnet N, Hani E, Dupont S et al (2000) Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 67:1470–1480CrossRefPubMedPubMedCentral

53.

Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F (2005) A synonymous coding polymorphism in the alpha 2-Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 54:2477–2481CrossRefPubMed

54.

Jensen MK, Bartz TM, Djousse L et al (2013) Genetically elevated fetuin-A levels, fasting glucose levels, and risk of type 2 diabetes: the cardiovascular health study. Diabetes Care 36:3121–3127CrossRefPubMedPubMedCentral

55.

Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK (2009) NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104:861–867CrossRefPubMed

56.

Stefan N, Schick F, Haring HU (2014) Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 371:2236–2237CrossRefPubMed

57.

Stefan N, Haring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60:2011–2017CrossRefPubMedPubMedCentral

58.

Stefan N, Haring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9:144–152CrossRefPubMed

59.

Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ (2012) Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metabol 97:4717–4723CrossRef

60.

Glumer C, Jorgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335–2340CrossRefPubMed

61.

Pomerleau J, McKeigue PM, Chaturvedi N (1999) Relationships of fasting and postload glucose levels to sex and alcohol consumption. Are American Diabetes Association criteria biased against detection of diabetes in women? Diabetes Care 22:430–433CrossRefPubMed

62.

Reynolds JL, Skepper JN, McNair R et al (2005) Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol JASN 16:2920–2930CrossRefPubMed

Titel: Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis
verfasst von: Vivian Yawei Guo
Bing Cao
Chunyan Cai
Kenneth King-yip Cheng
Bernard Man Yung Cheung
Publikationsdatum: 11.11.2017
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 1/2018
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-017-1068-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Physical activity levels of patients with type 2 diabetes in hospital and at home

New equations to estimate resting energy expenditure in obese adults from body composition

Development of a new scoring system to predict 5-year incident diabetes risk in middle-aged and older Chinese

Pancreatic imaging using an antibody fragment targeting the zinc transporter type 8: a direct comparison with radio-iodinated Exendin-4

Non-clostridial gas gangrene in a patient with poorly controlled type 2 diabetes mellitus on hemodialysis